Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $136.00. The company’s shares closed yesterday at $106.53.

Scotiabank analyst George Farmer reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $133.00. The company’s shares closed last Friday at $103.06. Farmer ...

Arcellx (NASDAQ:ACLX – Free Report) had its price objective boosted by Bank of America from $84.00 to $100.00 in a research ...

Revenue missed analyst estimates by 33%. Earnings per share (EPS) also missed analyst estimates by 21%. Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared ...

Arcellx (NASDAQ:ACLX – Free Report) had its target price increased by Robert W. Baird from $77.00 to $106.00 in a research ...

Based on the latest available data, ACLX has gained about 78.7% so far this year. Meanwhile, the Medical sector has returned an average of 4% on a year-to-date basis. This means that Arcellx, Inc. is ...